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EDITORIAL REVIEW
Light-chain deposition disease: Its relation with AL-type
amyloidosis
Among the systemic diseases associated with immunopro-
liferative syndromes is a recently identified light-chain depo-
sition disease (LCDD) LI, 21. It is characterized by the depo-
sition of an amorphous substance in various organs. The sub-
stance lacks staining properties and a fibrillar amyloid ultra-
structure, and it contains monoclonal light-chain (LC) deter-
minants, either kappa or lambda. Occasionally a heavy-chain
determinant is also found [2—5], which suggests that the term
LCDD, which is presently in use, could be replaced by light-
and heavy-chain deposition disease.
Although the diagnosis of LCDD can be suggested from light
microscopy examination, it is usually based on the im-
munofluorescent (IF) demonstration of monoclonal LC tissular
deposits. It is likely that the exact frequency of the disease has
been underestimated, because in past IF studies of kidney bi-
opsy specimens the sera against LC determinants have not
been routinely used, even in myeloma patients with unclassi-
fied nonamyloid glomerular lesions. Moreover, it is likely that
some of the cases of nodular giomerulosclerosis observed in
nondiabetic patients were in fact LCDD [6—101. Thus, al-
though the number of reported cases is increasing rapidly, it is
still low [1—5, 11—31], and the exact frequency remains un-
known. In addition, it must be stressed that LCDD may be ob-
served in the absence of malignant plasma cell proliferation.
This review is based on our own observations of 14 patients
with LCDD at Necker Hospital between 1973 and 1982 and on
the data in the literature. Several of our case reports have al-
ready been published, together with a series from Tenon Hos-
pital in Paris [30].
Renal histopathological changes
LCDD was first known as a nephropathy, and its renal le-
sions have been studied extensively [3. 301. It is characterized
by widespread tissue deposition of a material that lacks
amyloid characteristics and is reactive with one anti-LC anti-
serum (K or A) by IF. In the published cases, kappa-chain de-
posits [1—3, 5, 11—13, 20, 24, 25, 36, 571 were observed more
frequently than lambda-chain deposits were [3, 4, 15, 20, 25,
301, with a ratio of 4 to 1; however, it needs to be confirmed in
more cases whether there is an actual prevalence of kappa-
chain deposits. In very rare cases one heavy chain was found
together with the light chain [2—4, 18, 20, 30, 31]. In the Neck-
er series, 13 patients had kappa and one patient had lambda de-
posits; no patient had heavy-chain deposits, even when a
whole monoclonal Ig molecule was present in the serum (Ta-
ble 1).
In our experience, the most characteristic feature, found in
all cases studied by IF, is the fixation of monoclonal LC anti-
sera all along tubular basement membranes. By light micros-
I
copy, tubular lesions are characterized by a bright, refractile,
ribbon-like thickening of basement membranes, and this as-
pect is sufficiently recognizable to suspect LCDD before IF
study. Glomerular changes, however, are much less homo-
geneous. Nodular glomerulosclerosis, when present, is the
most striking lesion of LCDD by light microscopy, with an as-
pect similar to that observed in Kimmelstiel-Wilson glomeru-
lopathy. Among the 14 patients of the Necker series, nodular
glomerulosclerosis was found in 5 of them (patients 2, 3, 6, 12,
13, Table 1); in 7 additional patients, only thickening of the
glomerular basement membrane (GBM) was found by light mi-
croscopy; in the remaining 2 patients, mesangial areas and
GBM appeared normal. On IF examination, the glomerular pat-
tern is also heterogeneous. Glomerular fixation of LC antisera
was lacking in 3 patients. In the other 11 patients, fixation was
found: along the GBM with a markedly variable intensity, on
thickened non-nodular mesangium, and on mesangial nodules;
in the latter case, fixation was usually found on abnormal de-
posits present within the nodules, but could also be observed
on nodular membrane-like material in the absence of abnormal
deposits. The degree of fixation did not parallel the severity of
the lesions. In addition to the glomerular and tubular lesions,
abnormal deposits, positive in IF study, could be seen in the
interstitium and around the vessels.
We studied 11 patients by electron microscopy including the
5 patients with mesangial nodules [30] (Noel et al, in press).
The tubular deposits appeared as a finely granular material and
were found along the external aspect of the tubular basement
membranes. Tubular deposits and mesangial nodules appeared
as either a strongly dark, or a light, granular material. In every
case, the aspect of glomerular and tubular abnormal material,
dark or lighter material, was concordant. Thus, these morpho-
logic differences may reflect different compositions of the ma-
terial deposited.
Why certain patients have nodules and other patients do not
is not clear. In some patients, mild mesangial lesions can turn
to nodules, but this is not a rule, and we have observed nearly
normal glomeruli, even after the disease has been present a
number of years. Repeated renal biopsy examinations also
show that specific LCDD lesions such as LC deposits do not
usually disappear, even in treated patients. They can also re-
cur after transplantation in the grafted kidney [11, 12].
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Clinical renal features
Renal involvement is a constant feature of LCDD; it is the
major manifestation in most patients (as it was in all our pa-
tients, see Table 1). Some exceptions have been observed,
however, with the presenting symptoms being liver involve-
ment and portal hypertension in one patient [5, 17], and heart
and liver involvement in another [2]. Even in these two pa-
tients, renal involvement was demonstrated by renal biopsy or
at autopsy. The mean age at presentation is 55 years in our se-
ries, and this is in agreement with the age ranges reported in
the literature.
Proteinuria and renal failure are the main presenting fea-
tures. The degree of proteinuria varies greatly. In our series
(Table 1), 8 patients had proteinuria> 3 g per 24 hr, but only 4
of these had glomerular type proteinuria (all with the nephrotic
syndrome), the others having almost exclusively Bence Jones
proteinuria. In contrast, 2 patients had proteinuria below 1 g
per 24 hr, and 2 others had no proteinuria. The last 2 patients
had proteinuria of intermediate rate, 1.5 and 2 g per day. Re-
ported data suggest a high incidence of nephrotic syndrome in
LCDD, but its actual frequency may be less than is thought.
LCDD may often be undetected when there is only minimal
proteinuria, because biopsy is less often indicated here than it
is when nephrotic syndrome is suspected. It should be stressed
that, at least during the initial period, proteinuria does not nec-
essarily parallel the existence of nodular glomerulosclerosis.
Among the 4 patients in our series who had nephrotic syn-
drome, one had no glomerular nodules. On the contrary, 2
among the 5 patients with glomerular nodules (patients 2, 3, 6,
12, 13, Table 1) were those with the lowest levels of protein-
uria at presentation (their proteinuria, however, subsequently
increased).
The frequency and early appearance of renal failure are an-
other striking characteristic of LCDD, None of our 14 patients
had normal serum creatinine concentrations at presentation
(Table 1). The 11 patients of Tubbs et al [25] had renal failure,
as did 4 of the 6 reported by Seymour et al [24]. Most isolated
cases reported so far had renal failure. Declining renal func-
tion is the reason for referral in approximately one third of the
patients. When data on the course of renal failure before di-
agnosis are available, or after diagnosis in the few patients who
did not receive chemotherapy or corticosteroids, it is clear that
renal function declines rapidly, Six patients reported by Tubbs
et al [25] already had endstage renal failure when LCDD was
discovered. The two patients of Randall et al [2] who had mod-
erate renal insufficiency (serum creatinine, 2.6 and 4.7 mg/dl)
were receiving hemodialysis treatment less than one year later.
One patient of S$lling et al [9] died from uremia within 3
months.
In the Necker series, none of the 5 patients (patients 1, 7,
11, 12, 13, Table 1) who received no treatment or delayed treat-
ment retained stable renal function; all were treated by hemodi-
alysis within 2 to 23 months of presentation. Renal failure oc-
curs in LCDD with equal frequency in patients with either low
or heavy proteinuria. The disease thus differs from classical
myeloma, where renal failure is usually correlated with the de-
gree of proteinuria [35]. Other urinary abnormalities appear to
be of more secondary importance. Microscopic hematuria may
occur, but it was observed in only 2 patients in our series. In
both patients, it was less than io RBC per minute. The pres-
ence of hematuria is cited more often in the literature, but this
may be explained by the selection of patients presenting with
glomerular symptoms. Abundant hematuria was observed in 2
patients [20, 36], but both had marked glomerular extracapil-
lary cell proliferation, which is unusual in LCDD. Moderate ar-
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Table 1. Pertinent features in 14 patients with light-chain deposition disease, the Necker seriesa
Monoclonal
component
Age In blood In
Sex yr or urine tissues
Sr Follow- Organs
molesI Hematologic up Regular involved other
NS liter status months dialysis than kidneys"
No
Yes
Yes
No
No
No
8 M 55 K K 09 M 63 K K 1.510 M 69 K K 1011 M 49 K K 312 M 55 NF K 0.413 M 64 NF K 3.2
14 F 59 NF K 0.5
21 Yes Widespread (A) Dead Myeloma
2 Yes Liver (B) Dead Myeloma
12 Yes Unknown Dead LCDD
45 Yes Unknown Dead Unknown
Oc Yes Widespread (A) Dead LCDD
60 Yes Widespread (A) Dead Unknown
1.5 Yes Liver (B) Dead LCDD
24 No Liver (B) Alive
30 No Liver (B) Alive
9 No Unknown Alive
26 Yes Liver (B) Dead LCDD
72 Yes Liver (B) Alive
52 Yes Liver (B) Dead LCDD
36 No Unknown Alive
a Abbreviations are defined as follows: M, male; F, female; NS, nephrotic syndrome; HD, hemodialysis; LCDD, light-chain deposition disease;
NF, not found.
"Abbreviations in parentheses denote autopsy findings (A) or biopsy findings (B).
LCDD diagnosed at autopsy.
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terial hypertension is frequent, but it often precedes renal dis-
ease by several years, and the relation between the two may
be questioned.
In summary, LCDD nephropathy has two different present-
ing aspects: either glomerular nephropathy or chronic intersti-
tial nephropathy, both often associated with renal failure. In
the case of the nephrotic syndrome (with or without renal fail-
ure) without any history of myeloma, no symptom suggests
LCDD over other types of glomerulopathy. On the contrary,
interstitial nephropathy associated with rapidly progressive re-
nal failure is unusual, and in our present view such a picture
should suggest LCDD.
The occurrence of a nephrotic syndrome during malignant
plasma cell proliferation was synonymous with amyloidosis un-
til the discovery of LCDD. We now know that in myeloma pa-
tients LCDD is at least as frequent as amyloidosis (among the
last 30 patients we observed with myeloma, 4 had LCDD and
3 amyloidosis). On the other hand, a picture of interstitial
nephropathy, with or without renal failure, is usual in mye-
loma. However, in a myeloma patient with renal failure in the
absence of Bence Jones proteinuria, LCDD should be sus-
pected. In such myeloma patients, the incidence of LCDD may
be underestimated if renal biopsy is not performed.
Hematological findings
Since the first observations of Randall et al [2], confirmed by
subsequent reports, it has been clear that LCDD may occur (a)
in overt myeloma (or in occult myeloma presenting as a
nephropathy) or other malignant lymphoplasmacytic prolifera-
tion, or (b) in the absence of myeloma. The first of these pos-
sibilities is the most frequent. In the Necker series (Table 1), 9
patients had myeloma and one had unclassified nonmyeloma
lymphoplasmacytic proliferation. In the literature, two thirds
of LCDD cases are associated with malignant lym-
phoplasmacytic proliferation, essentially myeloma but also
lymphoma [25] and Waldenström disease [5]. It must be em-
phasized that the plasmacytic disease is frequently unknown
until LCDD nephropathy is diagnosed, and when recognized at
that time it often seems to be at an early stage, without osteo-
lysis or hypercalcemia and most often with moderate bone
marrow plasmacytosis.
In contrast with these patients, one third of LCDD cases
have no detectable myeloma at presentation. This was the case
in 4 patients of our series, even after careful, repeated inves-
tigations (Table 1). Two had only traces of monoclonal LCs in
the urine on immunoelectrophoresis; the other two had none,
even after repeated urine tests. Serum polyclonal Ig levels,
however, were depressed in 3 of them. Two of these four pa-
tients died from visceral extrarenal manifestations, 26 months
and more than 4 years after the diagnosis of LCDD had been
made. The other 2 are still alive, 3 and 6 years later. In none
of the 4 cases did a malignant plasmacytic proliferation be-
come detectable. In 2 of them only the discovery of monoclo-
nal LCs in the kidneys suggested the existence of lym-
phoplasmacytic disease. The hypothesis was confirmed by IF
study of bone marrow cells, showing as in the other patients a
monoclonal population producing LCs of the same type as
those found in renal deposits.
The course in similar cases of LCDD without detectable
myeloma is not usually indicated in the literature, or the fol-
low-up is short. But some patients have been followed for
rather long periods, up to 2 years in one patient [26] and 4 years
in another (patient 14 in [301; A. Meyrier, personal communi-
cation) with no signs of myeloma having appeared. In some pa-
tients without detectable circulating monoclonal Ig, IF exami-
nation of bone marrow showed, as in Necker patients, a mono-
clonal plasma cell population [3, 5, 14, 18].
Thus, LCDD can occur in all types of plasma cell dyscrasia,
among which are found both malignant and controlled popu-
lations. In this regard, LCDD is similar to AL-type
amyloidosis, which can also occur in the absence of myeloma;
it is known that in primary arnyloidosis most patients have
monoclonal Ig in serum or urine [37, 38] but that the plasma
cell clone that produces monoclonal Ig does not have malig-
nant characteristics. In LCDD, the absence of serum and uri-
nary Ig is relatively frequent (approximately 15% of the pa-
tients), and these observations may be compared with those of
the so-called nonsecretory myelomas. Often in this type of
myeloma, bone marrow cells actually synthesize abnormally
structured Ig, which are rapidly degraded after secretion [39,
40]. This finding has led to the search for similar structural
anomalies of LCs in LCDD (see the following section).
Finally, a third possibility for the occurrence of LCDD in
myeloma patients is the transformation of an initially typical
myeloma, without LC deposits, after chemotherapy and pos-
sibly as its consequence. Two patients [15, 18, 30] probably
have had such an evolution (see the following section).
Extrarenal manifestations
Extrarenal involvement during LCDD was demonstrated in
two patients by Randall et al in 1976 [2]. Other patients have
since been reported [5, 11, 15, 18, 25, 30]. It is not known to
what extent LCs are deposited in organs other than the kid-
neys, but it is likely to be frequent. In our series of 14 pa-
tients, we found extrarenal LC deposits in all 9 patients in
whom they were sought. Tissular LC deposits may be totally
asymptomatic and found only at autopsy. This is illustrated by
patient 6 (Table 1). Tubulointerstitial lesions and nodular gb-
merulosclerosis were found in 1976. Five years later, the pa-
tient died of complications resulting from renal failure, without
having had any extrarenal symptoms. Autopsy showed depos-
its of LCs in the blood vessel walls of most organs. Similar
nearly latent deposits were found in liver biopsy samples from
two other patients (patients 8 and 12, Table 1). In the last 6 pa-
tients with extrarenal LC deposits, clinical manifestations were
associated with the deposits, and functional failure often led to
death. In our experience, the most frequent complications are
hepatic and cardiac involvement.
Of these, liver involvement is the best documented. Clinical
signs are, first, hepatomegaly and moderate functional distur-
bance upon liver function tests. When the disease is more ad-
vanced, hepatic insufficiency arid portal hypertension can de-
velop. Two patients of the Necker series (patients 7 and 11, Ta-
ble 1) and one reported in the literature [5, 17] died with se-
vere hepatic insufficiency. Of our 14 patients, 8 underwent
histological liver study (Droz et al, in press). By light micros-
copy examination, all patients had abnormal chromophilic
material along sinusoids, in vascular walls, and in basement
membranes of biliary ductules. Portal areas were enlarged by
fibrosis and usually contained abnormal material. The distri-
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bution of lesions varied from patient to patient. Two showed
extremely mild lesions with nearly normal sinusoids. In the
others, the lesions were more marked, with dilated sinusoids
that were outlined by a thick, ribbon-like material. In one pa-
tient the lesions were particularly severe, with numerous rup-
tures of sinusoids resembling peliosis; in addition, annular
fibrosis with some inflammatory cells but without nodular re-
generation was noticed in this patient. Peliosis was also ob-
served in another patient [5, 17]. IF study was performed in 7
of our patients. In every one, monotypic LCs were found (A in
one and K in 6), and the LC type was the same as it was in the
kidney. Fixation was observed all along the sinusoids and in
portal areas. In the 2 patients with mild histologic abnormali-
ties, fixation was light on sinusoids and more marked in portal
areas. In the patient with annular fibrosis, light-chain fixation
was widespread, also occurring within the fibrosis. Electron
microscopy showed granular electron-dense material in the
Disse spaces (often centered on fine collagen fibers), between
hepatocytes, and along collagen fibers. In 3 patients, the granu-
lar material had a strongly electron-dense, nearly black appear-
ance; in the other patients the electron density was markedly
less intense. It must be stressed that in patients in whom renal
ultrastructural study was also available, granular material was
identical in the liver and the kidney, either dark or light in both
organs (Fig. 1).
Heart involvement also appears to be frequent. Of our 14 pa-
tients, 4 were thus affected: cardiomegaly in 3, congestive
heart failure in 2, cardiac rhythm and conduction disorders in
2. Two patients died of cardiac complications (patients 3 and
5, Table I). Autopsy data were available in 3 patients, includ-
ing one with symptomatic involvement. By light microscopy
examination, there were little changes except in the patient
who had clinical symptoms, in whom the myocardial fibers
were dissociated by fibrosis. IF study showed monotypic LC-
staining of the perivascular areas and within the vascular walls
in every patient, and of the external aspect of the myocardial
fibers in 2 patients.
Clinical neurological symptoms (CNS involvement or periph-
eral neuropathy, or both) were noted in 2 of our patients, but
no pathologic study was made. Other authors have observed,
besides liver [2, 5, 11, 181 and heart [2, 11] deposits, neurolog-
ic involvement with light chain deposits along the nerve fibers
and at the choroid plexus [2]. Cerebral arterial involvement
was reported by Colvin et a! [1], with cerebral hemorrhage ow-
ing to rupture of an arterial aneurysm, which developed close
to a light-chain deposit.
Deposits in the spleen have also been reported, as well as in
the lymph nodes, pancreas, thyroid gland, adrenal glands, and
GI tract [2, 11]. In 2 patients we found deposits in the large ab-
dominal vessels, both the veins (especially the portal vein) and
the arteries (aorta, mesenteric artery).
We did not find pulmonary deposits in the 3 patients stud-
ied, including the one who had pulmonary clinical symptoms.
Only one case of pulmonary LC deposits has so far been re-
ported [11]; in this patient, the deposits, located in the alveo-
lar walls, were disclosed at autopsy.
We studied the skin in 4 patients. In one myeloma patient
who had subcutaneous plasmacytic nodules, we found LC de-
posits similar to those found in other organs, around the plasma
cells. In the other 3, the skin was normal and we found no LC
deposits, Randall et al [21 and Tubbs et al [25] each reported a
patient with kappa-chain deposits in the skin, probably on nor-
mal-appearing skin.
In sum, what is remarkable is the widespread distribution of
LC deposition in all patients who have undergone a careful
study. Nevertheless, the natural history of visceral manifesta-
tions in LCDD is unclear at present because the number of pa-
tients studied is still low and pathologic studies are few (both
initial and repeated studies would be necessary in every pa-
tient). Renal involvement appears to be constant and usually
pr dominant. The recruitment of patients—most of them com-
ing from renal units—is only a partial explanation. Factors fa-
voring renal deposits of LCs could, for example, be linked to
special hemodynamic conditions in the kidney, to the renal ca-
tabolism of LCs, to their chemical and physiologic character-
istics, or to a particular affinity of LCs for kidney structures.
As discussed earlier, extrarenal deposits of LCs observed in
various organs can be entirely asymptomatic. It is still difficult
to determine whether this represents a relatively "benign"
evolution or merely an early stage of the disease, which will in-
evitably become more severe. This debate is well illustrated by
the follow-up of 2 of our patients. The first (patient 6, Table 1)
died 5 years after the diagnosis of LCDD was made. At au-
topsy, deposits were found in many organs, but they were
minimal and involved only the vessels, without severe visceral
lesions. This patient had been treated by chemotherapy during
the whole course of the disease, and a beneficial effect of this
treatment could be hypothesized. The example of another pa-
tient (patient 12, Table 1) illustrates that such a suggestion
should be considered with caution. This patient never received
chemotherapy and never had extrarenal manifestations. Liver
biopsy made 5 years after the discovery of renal LC deposits
showed only mild fixation of anti-kappa antisera on the portal
spaces and questionable fixation along the sinusoids, with no
other parenchymal alteration. Renal involvement had been se-
vere, however, and hemodialysis initiated a few months after
diagnosis of the disease. Thus, it appears that in some patients
LCDD remains almost exclusively localized in the kidneys and
that if it extends to other organs those deposits are insignifi-
cant and often asymptomatic. It is also possible to hypothesize
that either spontaneously or after chemotherapy the
plasmacytic clone that produced LCs capable of tissue depo-
sition may decrease or disappear, thus explaining that LC
deposition is slight in some patients, even after a long time.
It seems logical to hypothesize that the extent of tissue depo-
sition might depend on the amount of LCs capable of deposi-
tion and, consequently, on the size and synthetic rate of the
plasma cell clone that produces them. Two of our patients who
had no extrarenal manifestations had a normal number of bone
marrow plasma cells. On the other hand, it is not certain that
the large tumoral mass observed in myeloma patients with
LCDD necessarily correlates with intense LC deposition. For
example, in an IgG kappa myeloma patient in our series, study
of Ig biosynthesis by bone marrow plasma cells showed one
normal heavy chain and one abnormal K LC. The LC was se-
creted assembled with the heavy chain, thus constituting the
serum monoclonal peak, but it was also secreted as free LCs,
which were undetectable in serum and urine. This patient had
renal kappa LC deposits without a heavy chain, and it is likely
that the serum monoclonal Ig was not involved in the deposi-
Light-chain deposition disease 5
Fig. 1. Light-chain deposition disease aemonstrated by electron microscopy in 2 patients. A Renal biopsy sample shows granular electron-dense
material (arrow) on the external side of tubular basement membrane. B Liver biopsy sample from same patient shows identical granular elec-
tron-dense material (arrow) in Disse space and between hepatocytes. C Renal biopsy sample from a second patient shows very dark granular
electron-dense material (arrow) on the external side of tubular basement membrane. D Liver biopsy sample from this second patient shows iden-
tical very dark granular electron-dense material (arrow) along sinusoid. (Uranyl acetae and lead citrate stain; magnification, x 4500.) Abbrevia-
tions are: S, sinusoid; H, hepatocytes.
* I'.
,..t
4
6 Ganeval et a!
tion process. In this case, the magnitude of plasma cell mass
could be unrelated to the degree of LC deposition and the pa-
tient was free of extrarenal manifestations for 5 years.
Treatment of LCDD
Given the preceding uncertainties with regard to the natural
history of LCDD, it is difficult to determine what should be the
treatment in the only really difficult case, that is, when LCDD
occurs in the absence of myeloma. Since the disease is linked
to the production (and deposition) of Ig chains synthesized by
one plasma cell clone, it would seem logical to treat these pa-
tients by chemotherapy as in myeloma, and this was the de-
cision in most reported cases. The treatment then has two
aims: (a) improve or stabilize renal failure; (b) prevent extra-
renal deposition of LCs.
Overall analysis of our observations may suggest that treat-
ment favorably influences the evolution of renal function. In 11
patients who were followed long enough to permit such analy-
sis, 6 were treated early (patients 4, 6, 8, 9, 10, 14, Table 1)
and 5 were treated either late or not treated (patients 1, 7, 11,
12, 13, Table 1). In the treated group (5 with myeloma and one
without myeloma), only one (patient 6) has reached the point
of requiring hemodialysis, after 4 years. The others have re-
mained stable, or have improved (patients 4 and 9), with a fol-
low-up of 21 to 42 months. In contrast, all the patients of the
nontreated group (2 with myeloma and 3 without myeloma)
went to endstage renal failure and hemodialysis within 2, 3, 4,
18, and 22 months. However, it must be noted that the pa-
tients in this second group were seen at a more advanced stage
of renal insufficiency, with possibly irreversible pathologic le-
sions, whereas the treated patients had been seen earlier in the
course of the disease. Symptomatic management may have a
favorable effect on renal function, independent of chemo-
therapy. This might have been the case for the reported pa-
tient [26] whose renal function strikingly improved during
chemotherapy. This was possibly related to control of hyper-
tension and cardiac failure. Finally, it is even more difficult to
determine whether chemotherapy prevents extrarenal deposi-
tion, because it is difficult to assess the spontaneous evolution
of extrarenal involvement.
Thus, while awaiting more extensive data, one might pro-
pose—in the absence of detectable myeloma—the following
pragmatic attitude: when renal insufficiency is moderate, use
the same treatment as used for myeloma patients (alkylating
drugs plus prednisone) in an attempt to improve or stabilize the
renal disease. But in endstage renal failure hemodialyzed pa-
tients, initiate treatment only in the presence of extrarenal
manifestations likely to be the consequence of LC deposition.
Mechanism of LC deposition
The precise mechanism of tissue precipitation of LCs is not
known. Suggestions, however, are available. Studies per-
formed in a certain number of patients demonstrate frequent
abnormalities of the Ig chains secreted by the plasma cells.
This could suggest that structural abnormalities may be respon-
sible for their tissue deposition.
In the experiments performed by one of us [5, 18, 30, 31], Ig
biosynthesis by bone marrow cells was studied in 9 patients.
Cells from 7 out of the 9 patients produced abnormal 1g. Cells
from 4 patients synthetized only abnormal LCs, either short
(one patient) or large (3 patients). These LCs were secreted as
covalent polymers. In the other 3 patients, both heavy and light
chains were synthesized. In one patient, both chains were of
abnormal size. In the second, only the LCs were abnormal, and
the Ig chains were secreted as IgG molecules and free LCs. In
the third patient, the cells produced abnormal heavy chains (H)
and normal LCs with a partial assembly block at the half-mol-
ecule level (HL), and abnormally short LCs secreted as free
LCs.
Another striking finding in these 7 patients was a difference
in the apparent molecular weight between cytoplasmic and se-
creted LCs. Similar differences have been related to the addi-
tion of carbohydrates, which mainly takes place close to se-
cretion and modifies the mobility of proteins in acrylamide
gels. One could thus hypothesize that the LCs of these pa-
tients were glycosylated, and such a glycosylation in all cases
would be very unusual since glycosylated light chains are
found in only 15% or less of human myelomas [41—43]. Evi-
dence of a glycosylation of the LCs was established by the
studies of the serum Ig in one patient of our series and in an-
other patient reported in the literature [31] (E. Mihaesco, un-
published results), and by biosynthetic experiments in the pres-
ence of tunicamycine in the latter patient.
Other investigators have found similar abnormalities in pa-
tients with LCDD. Gallo, Feiner, and Buxbaum [3] reported a
patient whose bone marrow cells produced normal-sized
lambda LCs and abnormal (short) gamma chains; in this pa-
tient, both heavy and light chains were found in the kidney. In
a LCDD patient described by SØlling and Askjaer [9], kappa-
chain polymers were found.
These results tend to support the hypothesis that major
structural abnormalities favor the deposition of Ig chains; how-
ever, the deposition in some cases of LCs that lack these ab-
normalities suggests the intervention of additional mecha-
nisms, as discussed below.
The mechanisms leading to the production of abnormal Ig
chains could be a genetic mutation, Structural and chemical ab-
normalities, similar to those observed in the patients just de-
scribed, have been obtained in mice as a result of chemical mu-
tagenesis [39, 44—46], especially with melphalan [41, 47, 481. A
counterpart of these experimental data was showiby Hobbs
[49], who observed such a mutation in a myeloma patient, and
is suggested in at least the two following patients with LCDD.
One patient of our series had a common Bence Jones lambda
myeloma, and an initial renal biopsy just before chemotherapy
showed a typical Bence Jones cast nephropathy without LC
deposits. One year later, this patient developed severe, rapidly
progressive, multivisceral LCDD, documented at autopsy. An-
other patient [18] presented first with a common IgA myeloma
and developed the manifestations of tissue deposition of alpha
and kappa chains after 8 months of melphalan therapy at a time
when bone marrow plasmacytosis increased, whereas the se-
rum monoclonal IgA level sharply decreased. Biosynthesis ex-
periments showed obvious abnormalities of the a and Kchains
produced (whereas the original serum IgA was normal).
But in most patients (including several with demonstrated
structurally abnormal Ig), LCDD was observed before chemo-
therapy was initiated, and if a somatic mutation is responsible
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for the production of abnormal Ig, other unknown mutagenic
events must be involved.
In addition to structural abnormalities, glycosylation of the
Ig molecules and their trend to assemble into high molecular
weight polymers might play a role in their deposition. It is note-
worthy that structural abnormalities without glycosylation
have been noted in "non-secreting" myeloma patients without
LCDD [39, 401. It is also worth recalling that it has been shown
that LCs are glycosylated in patients with diabetes and that
glomerular lesions in Kimmelstiel Wilson nephropathy and in
LCDD glomeruloscierosis are nearly identical by light mi-
crosopy, which could be more than a morphologic similarity.
In contrast with the results just discussed, there is now also
evidence that apparently normal Ig may be susceptible to vis-
ceral deposition. Normal-sized LCs secreted as dimers and
monomers were found in 2 of our patients [30, 31] in whom the
results of biosynthesis experiments were indistinguishable from
those obtained in common Bence Jones myelomas without
LCDD, and in another patient [141. In addition, a normal-sized
monoclonal IgA was found in the serum of a patient with ai<
deposits (C. Mihaesco and E. Mihaesco, unpublished results).
It could be hypothesized that normal-sized Ig may bear other
(or minor) abnormalities, as has been demonstrated in several
variants of LCs producing murine myeloma cells, and that this
could lead to their deposition. Other mechanisms, however,
are probably involved in LC deposition, such as the isoelectric
point (p1) of LCs, or their possible affinity for biological mem-
branes. The most likely to play a role could be the p1 because
a low p1 would reduce LC filtration through the negatively
charged glomerular membranes [50], and would therefore in-
crease the amount delivered to the postglomerular capillaries,
susceptible to peritubular deposition. A recent study of pa-
tients with kidney disease and paraproteinemia [51] found a
correlation between the p1 of the LCs (calculated from its elec-
trophoretic mobility) and the type of renal lesions; patients
with LCs of low electrophoretic mobility (high p1) had numer-
ous tubular casts; conversely, those with high electrophoretic
mobility (low p1) had rare casts , and 3 of them had deposits of
LCs (2 had amyloid, and one had LCDD). With regard to such
a mechanism, polymerization of the LCs when associated with
a low p1 would further predispose to renal deposition.
LCDD and AL-type amyloidosis
With LCDD, a new aspect of LC deposition in tissues has
been recognized. From the data presented, it is clear that AL-
type amyloidosis and LCDD, although they have marked dif-
ferences, also have features in common. Both are character-
ized by polyvi5ceral extracellular deposition (with a similar to-
pography) of Ig-derived material. Although amyloid deposits
are principally derived from A LCs and nonamyloid LCDD de-
posits from K LCs, there are exceptions in both diseases. AL-
type amyloid substance is known to usually contain an LC frag-
ment related to the variable region, whereas the strong IF-
staining with anti-LC sera in LCDD suggests that amyloid de-
posits include at least part of the constant region. It has been
shown, however, that AL amyloid deposits can include whole
or even large LCs [56]; finally, a major difference between AL-
type amyloidosis and LCDD lies in their ultrastructural as-
pect. The beta-pleated fibrillar structure of amyloid substance
differs from the structure of LC deposits, which are character-
ized by their granular, nonfibrillar aspect. To explain the non-
amyloidogenic character of the LCs involved in LCDD, it has
been hypothesized [52, 53] that these chaiins could be defec-
tive in the variable region critical for amyloid formation, or that
the lack of periodicity of LCDD substance could be related to
the aberrant length of light chains [54].
The study of one of us (Preud'homme et al, to be published
in detail elsewhere) of Ig biosynthesis by bone marrow cells in
13 patients with primary amyloidosis and 2 with myeloma and
amyloidosis indicate that, in AL-type amyloidosis as in LCDD.
the structure of the Ig chain can be abnormal, including that of
heavy chains. For this study, cytoplasmic Ig (clg) were stud-
ied by direct IF. For accurate counting of plasma cells contain-
ing the various clg chains, as many as 5,000 to 10,000 bone
marrow cells per IF slide were counted when required. Ig bi-
osynthesis was studied by polyacrylamide SDS-gel electropho-
resis of labeled ('4C or 3H amino acids) Ig molecules [5, 30].
Four patients with amyloidosis secondary to various diseases
were also studied as controls.
In patients with secondary amyloidosis, there was a normal
distribution of bone marrow plasma cells by IF (y> a > i >
6 and K > A), and the sum (y + a + +6) of heavy-chain-
containing cells equalled that of (K + A) light-chain-positive
cells. Biosynthesis experiments showed the synthesis of nor-
mal-sized Ig molecules, without free light-chain secretion.
Conversely, abnormalities were found in almost all patients
with AL-type amyloidosis. Monotypic Ig were demonstrated
by IF in all but 2 patients, including three patients without de-
tectable monoclonal Ig in senim or urine. Data on Ig biosyn-
thesis were available in 9 patients with AL amyloidosis. A
common finding was excessive production of LCs (and this was
the case in the patient without detectable monotypic plasma
cell population, in whom a huge excess of free LCs was syn-
thesized). A small molecular-weight fragment of the size of half
an LC, which was usually not secreted, was found in most pa-
tients. Finally, unusual Ig synthesis patterns were observed in
certain patients: synthesis of a 31-kilodalton kappa chain that
was secreted as a decamer (one patient), abnormal assembly of
the monoclonal IgA produced by the cells (one patient), and
synthesis of monoclonal IgG with abnormally short heavy
chains (two patients). Ig biosynthesis is therefore clearly
heterogeneous in AL-type amyloidosis and varies from patient
to patient, from the production of free LCs with an apparently
normal molecular weight to that of clearly abnormal Ig chains,
including heavy chains. Ig abnormalities demonstrated in the
preceding study confirm the findings of other investigators [55,
56] who occasionally found abnormalities of Ig in AL-type
amyloidosis. Biosynthesis experiments in amyloidosis did not
show any data suggestive of LC glycosylation, in contrast to
LCDD. As a whole, it is likely that the probable mechanisms
of tissue deposition in most cases of AL-type amyloidosis (al-
terations caused by post-secretory proteolysis of LCs secreted
as normal-sized chains but especially sensitive to proteolysis
[57]) and LCDD (synthesis of grossly abnormal Ig chains) are
different, but that, in some patients, these mechanisms might
be quite similar. Thus, the occurrence of intermediate forms
(with deposits featuring both amyloidosis and LCDD) can be
expected and indeed such a case has been recently and briefly
reported [56].
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Conclusion
In plasma cell dyscrasias (including myeloma, LCDD, and
AL amyloidosis), the clinical features depend critically on the
substances released by the "dysregulated" plasma cell clone:
for example, osteoclast activating factor in some mycloma pa-
tients with severe bone involvement [581; potentially nephro-
toxic monoclonaJ light chains in Bence Jones myeloma leading
to the classical myeloma kidney [35]; abnormal light chains
prone to tissue deposition in LCDD or light chains highly sus-
ceptible to proteolysis in macrophage lysosonies [59] in AL
amyloidosis. Further investigations are needed to clarify the
cell defects leading to such a synthesis, as well as the inter-
mediary mechanisms involved.
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